Clinical Trials

40 enrolled

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT07069595 2026-04-13

PREDICT-RD

78 enrolled

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT07524114 2026-04-13

SHERLOCK

BreastDermatologicGastrointestinalHead & NeckThoracic

7,000 enrolled

Breast Neoplasms, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Neoplasms, Unknown Primary, Urogenital Neoplasms, Neoplasm, Residual

NCT04841148 2026-04-09

PALAVY

96 enrolled

Breast Neoplasms, Neoplasm, Residual

NCT05735717 2026-04-06

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

CNSClassical hematologyLymphoidOther hematologic neoplasm

70 enrolled

Chromosome 7, monosomy, Anemia, Refractory, with Excess of Blasts, Chromosome Aberrations, Influenza, Human, Neurofibromatosis 1, Leukemia, Myeloid, Acute, beta-Thalassemia, Neoplasm, Residual, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myelomonocytic, Juvenile

NCT07136077 2026-04-06

A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

20 enrolled

Gastrointestinal

Colorectal Neoplasms, Neoplasm, Residual

NCT06875609 2026-03-30

ctDNA in Cutaneous Squamous Cell Carcinoma

60 enrolled

Dermatologic

Skin Neoplasms, Neoplasm, Residual

NCT07134088 2026-03-30

A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia

104 enrolled

Burkitt Lymphoma, Recurrence, Neoplasm, Residual

NCT07500441 2026-03-30

Digital PCR of CHIP and MR for MRD Monitoring After Allo-HSCT in AML

Other hematologic neoplasm

100 enrolled

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT05232916 2026-03-19

FLAMINGO-01

Phase 3 Recruiting

750 enrolled

Breast Neoplasms, Neoplasm, Residual

NCT06500273 2026-03-18

ALPHA3

250 enrolled

Lymphoma, Large B-Cell, Diffuse, Neoplasm, Residual

NCT06134375 2026-03-12

A Study of Tetrathiomolybdate (TM) Plus Capecitabine

204 enrolled

Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT06951646 2026-03-09

ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)

70 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm, Residual

NCT05708235 2026-03-05

MiRaDoR

976 enrolled

Breast Neoplasms, Neoplasm, Residual

NCT06130995 2026-03-05

Relugolix + Enzalutamide Study in High-Risk Prostate Cancer

46 enrolled

Pathologic Complete Response, Neoplasm, Residual

NCT07211178 2026-03-04

GEMINI Breast

900 enrolled

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT07291921 2026-03-03

To Conduct Multi-omics Integrated Studies in Peripheral Blood, Such as Fragment Omics, Metabolomics and Epigenetics, and Establish Non-invasive Dynamic Follow-up Monitoring Programs During Perioperative and Postoperative Periods (Observational Study)

100 enrolled

Thoracic

Lung Neoplasms, Neoplasm, Residual

NCT07441291 2026-02-27

CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT

Phase 3 Recruiting

70 enrolled

Neoplasm, Residual

NCT07148180 2026-02-05

A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax

Other hematologic neoplasm

31 enrolled

Leukemia, Leukemia, Myeloid, Acute, Neoplasm, Residual, Hematologic Neoplasms

NCT06693830 2026-01-23

ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL

Phase NA Recruiting

40 enrolled

Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Neoplasm, Residual

NCT01499394 2026-01-21

Caris Biorepository Research Protocol

100,000 enrolled

Neoplasms, Neoplasm, Residual

NCT07356882 2026-01-21

EURHOLY

400 enrolled

Neoplasm, Residual

NCT06358430 2026-01-15

Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)

42 enrolled

Gastrointestinal

Colorectal Neoplasms, Neoplasm, Residual

NCT07025785 2026-01-15

Molecular Residual Disease Assessment in a Representative Diverse Population of Patients With Early-stage Breast Cancer

Phase NA Recruiting

100 enrolled

Breast Neoplasms, Lymphatic Metastasis, Neoplasm, Residual

NCT04991103 2025-12-31

Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)

40 enrolled

Plasma cell

Amyloidosis, Multiple Myeloma, Neoplasm, Residual

NCT05929222 2025-12-24

FIL_GAZEBO

Phase 3 Recruiting

190 enrolled

Lymphoma, Lymphoma, Follicular, Neoplasm, Residual

NCT07280494 2025-12-12

S101MRD

18 enrolled

Lymphoma, Neoplasm, Residual

NCT05595408 2025-12-09

Circulating and Urine Tumor DNA Dynamics Predict Minimal Residual Disease and Recurrence Risk in Locally Advanced Upper Tract Urothelial Carcinoma

84 enrolled

Neoplasm, Residual

NCT07178847 2025-12-01

NeckTAR-IN

Phase NA Recruiting

59 enrolled

Neoplasm, Residual

NCT04707300 2025-11-20

HTLP-ONCO

Other hematologic neoplasm

10 enrolled

Leukemia, Myeloid, Acute, Neoplasm, Residual, Hematologic Neoplasms

NCT03326921 2025-11-14

HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant